Simulations Plus (NASDAQ:SLP) Rating Reiterated by William Blair

William Blair reissued their outperform rating on shares of Simulations Plus (NASDAQ:SLP) in a research report report published on Thursday, Benzinga reports. William Blair also issued estimates for Simulations Plus’ Q4 2024 earnings at $0.06 EPS, FY2024 earnings at $0.54 EPS, Q2 2025 earnings at $0.19 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at $0.67 EPS.

SLP has been the subject of several other research reports. Oppenheimer boosted their price objective on shares of Simulations Plus from $55.00 to $65.00 and gave the stock an outperform rating in a research report on Thursday, June 13th. KeyCorp assumed coverage on shares of Simulations Plus in a research report on Monday, July 29th. They issued an overweight rating and a $47.00 price objective for the company. Craig Hallum reiterated a buy rating and set a $56.00 target price on shares of Simulations Plus in a research report on Wednesday, July 3rd. Finally, JMP Securities assumed coverage on shares of Simulations Plus in a research report on Tuesday, July 16th. They set a market perform rating for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $56.00.

Simulations Plus Trading Up 0.8 %

NASDAQ:SLP opened at $32.50 on Thursday. The firm has a 50 day moving average of $37.67 and a 200-day moving average of $42.96. Simulations Plus has a 1 year low of $32.22 and a 1 year high of $51.22. The stock has a market capitalization of $650.33 million, a P/E ratio of 67.71 and a beta of 0.70.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Tuesday, July 2nd. The technology company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.04. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The firm had revenue of $18.54 million during the quarter, compared to analysts’ expectations of $17.92 million. During the same quarter in the previous year, the company posted $0.20 EPS. Simulations Plus’s revenue was up 14.2% on a year-over-year basis. As a group, analysts forecast that Simulations Plus will post 0.51 EPS for the current fiscal year.

Simulations Plus Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 5th. Shareholders of record on Monday, July 29th were given a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend was Monday, July 29th. Simulations Plus’s payout ratio is 50.00%.

Insider Buying and Selling at Simulations Plus

In other news, Director Daniel L. Weiner sold 750 shares of the business’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $49.32, for a total value of $36,990.00. Following the completion of the transaction, the director now owns 7,009 shares of the company’s stock, valued at approximately $345,683.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Daniel L. Weiner sold 750 shares of the business’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $49.32, for a total value of $36,990.00. Following the completion of the transaction, the director now owns 7,009 shares of the company’s stock, valued at approximately $345,683.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $46.71, for a total transaction of $934,200.00. Following the completion of the transaction, the director now directly owns 3,540,857 shares of the company’s stock, valued at approximately $165,393,430.47. The disclosure for this sale can be found here. In the last 90 days, insiders sold 60,750 shares of company stock worth $2,467,390. Insiders own 20.90% of the company’s stock.

Hedge Funds Weigh In On Simulations Plus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company boosted its stake in Simulations Plus by 7.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock worth $311,000 after purchasing an additional 456 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in Simulations Plus in the 2nd quarter worth $811,000. Public Sector Pension Investment Board boosted its stake in Simulations Plus by 6.4% in the 2nd quarter. Public Sector Pension Investment Board now owns 35,227 shares of the technology company’s stock worth $1,713,000 after purchasing an additional 2,122 shares during the period. Dimensional Fund Advisors LP boosted its stake in Simulations Plus by 10.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock worth $20,128,000 after purchasing an additional 37,992 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in Simulations Plus by 1.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 54,813 shares of the technology company’s stock worth $2,665,000 after purchasing an additional 784 shares during the period. 78.08% of the stock is owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.